Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage
Status:
Withdrawn
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
PITCH-ER is an ancillary study of PITCH-HF (NCT01910389). The goal of the PITCH-ER ancillary
study is to evaluate the rate of decline in renal function and frequency of development of
acute kidney injury (AKI) in patients enrolled in PITCH-HF (who have heart failure and
pulmonary hypertension) treated with chronic tadalafil treatment compared to placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
HealthCore-NERI National Heart, Lung, and Blood Institute (NHLBI) New England Research Institutes